GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » EV-to-EBIT

Oxurion NV (XBRU:OXUR) EV-to-EBIT : -0.61 (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oxurion NV's Enterprise Value is €11.56 Mil. Oxurion NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.95 Mil. Therefore, Oxurion NV's EV-to-EBIT for today is -0.61.

The historical rank and industry rank for Oxurion NV's EV-to-EBIT or its related term are showing as below:

XBRU:OXUR' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.38   Med: -0.46   Max: 40.79
Current: -0.61

During the past 13 years, the highest EV-to-EBIT of Oxurion NV was 40.79. The lowest was -3.38. And the median was -0.46.

XBRU:OXUR's EV-to-EBIT is ranked worse than
100% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs XBRU:OXUR: -0.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Oxurion NV's Enterprise Value for the quarter that ended in Dec. 2023 was €13.80 Mil. Oxurion NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.95 Mil. Oxurion NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -137.30%.


Oxurion NV EV-to-EBIT Historical Data

The historical data trend for Oxurion NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV EV-to-EBIT Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.20 -2.59 -2.47 -0.39 -0.73

Oxurion NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 - -0.39 - -0.73

Competitive Comparison of Oxurion NV's EV-to-EBIT

For the Biotechnology subindustry, Oxurion NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxurion NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oxurion NV's EV-to-EBIT falls into.



Oxurion NV EV-to-EBIT Calculation

Oxurion NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=11.561/-18.948
=-0.61

Oxurion NV's current Enterprise Value is €11.56 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxurion NV  (XBRU:OXUR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oxurion NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-18.948/13.800514
=-137.30 %

Oxurion NV's Enterprise Value for the quarter that ended in Dec. 2023 was €13.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxurion NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-18.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxurion NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oxurion NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxurion NV (XBRU:OXUR) Business Description

Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines